Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research

Perioperative chemotherapy plays a very important role in the management of muscle-invasive bladder cancer (MIBC). Level I evidence from several large randomized clinical trials and a large meta-analysis support the use of cisplatin-based neoadjuvant chemotherapy (NAC) in this patient population (1).